Abstract | OBJECTIVE: STUDY DESIGN: Forty-five women previously treated for 6 months with nafarelin, who had recurrent symptoms and signs of endometriosis, received 400 mcg/day of nafarelin intranasally for 3 months. Efficacy was evaluated by changes in severity of symptoms and signs. Lumbar bone mineral density was measured by dual-energy x-ray absorptiometry and distal radius bone mineral density by single-photon absorptiometry. Bone mineral density was also measured in 10 control volunteers. RESULTS: Repeated 3-month treatment significantly alleviated recurrent symptoms and signs of endometriosis. Lumbar bone mineral density decreased significantly by a mean of 2% at the end of treatment; this loss was restored within 3 to 6 months after treatment completion. No bone mineral density decline occurred in the radius. Bone mineral density changes in the control group were statistically insignificant. CONCLUSIONS: A repeated 3-month course of nafarelin treatment significantly relieved recurrent endometriotic symptoms and signs without sustained loss of bone mineral density.
|
Authors | G D Adamson, W L Heinrichs, M R Henzl, A A Yuzpe, C Bergquist, J J Jacobson, S Eriksson, L Kwei, S M Gilbert |
Journal | American journal of obstetrics and gynecology
(Am J Obstet Gynecol)
Vol. 177
Issue 6
Pg. 1413-8
(Dec 1997)
ISSN: 0002-9378 [Print] United States |
PMID | 9423744
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Hormones
- Nafarelin
- Estradiol
|
Topics |
- Adult
- Bone Density
- Endometriosis
(drug therapy, metabolism)
- Estradiol
(blood)
- Female
- Hormones
(adverse effects, therapeutic use)
- Humans
- Menstrual Cycle
(blood)
- Middle Aged
- Nafarelin
(adverse effects, therapeutic use)
- Recurrence
- Retreatment
- Treatment Outcome
|